IPA Best of Health Awards
FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers
The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate
Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
Approximately 18,740 new cases of CLL have been diagnosed in the US this year
Amgen’s supplemental Biologics License Application for Blincyto approved by FDA
The approval for the leukaemia drug was supported by additional data from two phase 3 studies
Sanofi and Innate Pharma expand cancer therapeutics collaboration
The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology
ICR twin study indicates childhood leukaemia begins in the womb
The study, published in Leukemia, will help clinicians advise parents of twins with ALL
Daiichi gets breakthrough status for pre-NDA leukaemia drug
Quizartinib could have an advantage over rival drug Rydapt
NICE to look again at Pfizer’s Besponsa after appeal
The blood cancer medicine was originally turned down on cost-effectiveness grounds
NICE set to reject Pfizer’s leukaemia drug Besponsa
Firm plans to appeal the final appraisal determination on its orphan drug
FDA clears Pfizer’s leukaemia drug Besponsa
The breakthrough treatment is the first CD22-targeted ADC to be approved in the US
NICE rejects Pfizer’s antibody drug for leukaemia
Trial shows no survival benefit from Besponsa compared to current treatment
